Inhibition of Ezrin suppresses cell migration and invasion in human nasopharyngeal carcinoma

Tang,Yuanyuan; Sun,Xiuzhen; Yu,Shen; Bie,Xu; Wang,Jizhe; Ren,Lidan

doi:10.3892/ol.2019.10370

Inhibition of Ezrin suppresses cell migration and invasion in human nasopharyngeal carcinoma

Authors:
- Yuanyuan Tang
- Xiuzhen Sun
- Shen Yu
- Xu Bie
- Jizhe Wang
- Lidan Ren
View Affiliations

Affiliations: Department of Otolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Dalian Medical University, Dalian, Liaoning 116027, P.R. China, State Key Laboratory of Structural Analysis for Industrial Equipment, Dalian University of Technology, Dalian, Liaoning 116023, P.R. China, Department of Oncology, The 210th Hospital of PLA, Dalian, Liaoning 116000, P.R. China
Published online on: May 17, 2019 https://doi.org/10.3892/ol.2019.10370
Pages: 553-560
Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is one of the most severe types of malignant cancer of the head and neck as it is difficult to treat. Ezrin is highly expressed in numerous types of cancer. However, the role of Ezrin in NPC has not been fully investigated and further studies are required in order to uncover its therapeutic potential in the treatment of NPC. The aim of the present study was to investigate the expression of Ezrin in human NPC and to evaluate the effect of knockdown of Ezrin using small interfering (si)‑RNA on NPC cell migration and invasion. The expression levels of Ezrin were determined using reverse transcription‑quantitative polymerase chain reaction, immunohistochemical staining and western blotting. Following transfection of Ezrin‑siRNA into NPC cells, cell invasion and migration were analyzed and the mRNA expression levels of matrix metalloproteinase(MMP)‑2 and MMP9 were determined. The results revealed that the expression of Ezrin was markedly increased in human NPC tissue samples compared with normal adjacent nasopharyngeal tissue samples. Ezrin was also highly expressed in the NPC cell lines 6‑10B and C6661 when compared with the normal nasopharyngeal cell line NP69. Transfection of NPC cell lines with siRNA targeting Ezrin significantly inhibited NPC cell migration and invasion, and downregulated the mRNA expression level of MMP2; however, no effect was observed on MMP9 mRNA expression. At the same time, knockdown of Ezrin significantly decreased the expression levels of phosphatidylinositol 3‑kinase (PI3K) and phosphorylated protein kinase B (Akt), which downregulated the mRNA expression of MMP2. In conclusion, the results revealed that knockdown of Ezrin suppressed NPC migration and invasion by reducing the mRNA expression of MMP2 via the PI3K/Akt signaling pathway. These results highlight the important role of Ezrin in NPC cell migration and invasion. In addition, they indicate that silencing of Ezrin may serve as a potential therapeutic strategy to treat human NPC.

View Figures

View References

1	Wei WI and Sham JS: Nasopharyngeal carcinoma. Lancet. 365:2041–2054. 2005. View Article : Google Scholar : PubMed/NCBI
2	Chan JY: Surgical management of recurrent nasopharyngeal carcinoma. Oral Oncol. 50:913–917. 2014. View Article : Google Scholar : PubMed/NCBI
3	Stoker SD, Van Diessen JN, de Boer JP, Karakullukcu B, Leemans CR and Tan IB: Current treatment options for local residual nasopharyngeal carcinoma. Curr Treat Options Oncol. 14:475–491. 2013. View Article : Google Scholar : PubMed/NCBI
4	Ong YK, Solares CA, Lee S, Snyderman CH, Fernandez-Miranda J and Gardner PA: Endoscopic nasopharynxgectomy and its role in managing locally recurrent nasopharyngeal carcinoma. Otolaryngol Clin North Am. 44:1141–1154. 2011. View Article : Google Scholar : PubMed/NCBI
5	Bretscher A: Purification of the intestinal microvillus cytoskeletal proteins villin, fimbrin, and Ezrin. Methods Enzymol. 134:24–37. 1986. View Article : Google Scholar : PubMed/NCBI
6	Majander-Nordenswan P, Sainio M, Turunen O, Jääskeläinen J, Carpén O, Kere J and Vaheri A: Genomic structure of the human Ezrin gene. Hum Genet. 103:662–665. 1998. View Article : Google Scholar : PubMed/NCBI
7	Egerton M, Burgess WH, Chen D, Druker BJ, Bretscher A and Samelson LE: Identification of Ezrin as an 81-kDa tyrosine-phosphorylated protein in T cells. J Immunol. 149:1847–1852. 1992.PubMed/NCBI
8	Hiscox S and Jiang WG: Ezrin regulates cell-cell and cell-matrix adhesion, a possible role with E-cadherin/beta-catenin. J Cell Sci. 112:3081–3090. 1999.PubMed/NCBI
9	Crepaldi T, Gautreau A, Comoglio PM, Louvard D and Arpin M: Ezrin is an effector of hepatocyte growth factor-mediated migration and morphogenesis in epithelial cells. J Cell Biol. 138:423–434. 1997. View Article : Google Scholar : PubMed/NCBI
10	Deng X, Tannehill-Gregg SH, Nadella MV, He G, Levine A, Cao Y and Rosol TJ: Parathyroid hormone-related protein and Ezrin are upregulated in human lung cancer bone metastases. Clin Exp Metastasis. 24:107–119. 2007. View Article : Google Scholar : PubMed/NCBI
11	Akisawa N, Nishimori I, Iwamura T, Onishi S and Hollingsworth MA: High levels of Ezrin expressed by human pancreatic adenocarcinoma cell lines with high metastatic potential. Biochem Biophys Res Commun. 258:395–400. 1999. View Article : Google Scholar : PubMed/NCBI
12	Kang YK, Hong SW, Lee H and Kim WH: Prognostic implications of Ezrin expression in human hepatocellular carcinoma. Mol Carcinog. 49:798–804. 2010.PubMed/NCBI
13	Freeman WM, Walker SJ and Vrana KE: Quantitative RT-PCR: Pitfalls and potential. Biotechniques. 26:112–125. 1999. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data usingreal-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Takahashi M, Sugiura T, Abe M, Ishii K and Shirasuna K: Regulation of c-Met signaling by the tetraspanin KAI-1/CD82 affects cancer cell migration. Int J Cancer. 121:1919–1929. 2007. View Article : Google Scholar : PubMed/NCBI
16	Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang D, Zeng H and Liu Z: CD151 promotes cancer cell metastasis via integrins α3 β1 and α6 β1 in vitro. Mol Med Rep. 6:1226–1230. 2012. View Article : Google Scholar : PubMed/NCBI
17	Spano JP, Busson P, Atlan D, Bourhis J, Pignon JP, Esteban C and Armand JP: Nasopharyngeal carcinomas: An update. Eur J Cancer. 39:2121–2135. 2003. View Article : Google Scholar : PubMed/NCBI
18	Chiang AC and Massagué J: Molecular basis of metastasis. N Engl J Med. 359:2814–2823. 2008. View Article : Google Scholar : PubMed/NCBI
19	Peng S, Fan S, Li X, Wang L, Liu H, Zhou M, Wang L, Shen S and Li G: The expression of Ezrin in NPC and its interaction with NGX6, a novel candidate suppressor. Cancer Sci. 98:341–349. 2007. View Article : Google Scholar : PubMed/NCBI
20	Martin TA, Harrison G, Mansel RE and Jiang WG: The role of the CD44/Ezrin complex in cancer metastasis. Crit Rev Oncol Hematol. 46:165–186. 2003. View Article : Google Scholar : PubMed/NCBI
21	Hunter KW: Ezrin, a key component in tumor metastasis. Trends Mol Med. 10:201–204. 2004. View Article : Google Scholar : PubMed/NCBI
22	Poullet P, Gautreau A, Kadaré G, Girault JA, Louvard D and Arpin M: Ezrin interacts with focal adhesion kinase and induces its activation independently of cell-matrix adhesion. J Biol Chem. 276:37686–37691. 2001. View Article : Google Scholar : PubMed/NCBI
23	Krishnan K, Bruce B, Hewitt S, Thomas D, Khanna C and Helman LJ: Ezrin mediates growth and survival in Ewing's sarcoma through the AKT/mTOR, but not the MAPK, signaling pathway. Clin Exp Metastasis. 23:227–236. 2006. View Article : Google Scholar : PubMed/NCBI
24	Hatzoglou A, Ader I, Splingard A, Flanders J, Saade E, Leroy I, Traver S, Aresta S and de Gunzburg J: Gem associates with Ezrin and acts via the Rho-GAP Protein Gmip to down-regulate the Rho pathway. Mol Biol Cell. 18:1242–1252. 2007. View Article : Google Scholar : PubMed/NCBI
25	Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X, et al: Rho kinase phosphorylation promotes Ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res. 71:1721–1729. 2011. View Article : Google Scholar : PubMed/NCBI
26	Ou-Yang M, Liu HR, Zhang Y, Zhu X and Yang Q: ERM stable knockdown by siRNA reduced in vitro migration and invasion of human SGC-7901 cells. Biochimie. 93:954–961. 2011. View Article : Google Scholar : PubMed/NCBI
27	Yang XY, Ren CP, Wang L, Li H, Jiang CJ, Zhang HB, Zhao M and Yao KT: Identification of differentially expressed genes in metastatic and non-metastatic nasopharyngeal carcinoma cells by suppression subtractive hybridization. Cell Oncol. 27:215–223. 2005.PubMed/NCBI
28	Shen ZH, Chen XY and Chen J: Impact of up-regulation Ezrin expression by Epstein-Barr virus latent membrane protein 1 on metastasis ability of nasopharyngeal carcinoma cells. Ai Zheng. 27:165–169. 2008.(In Chinese). PubMed/NCBI
29	Khokha R and Denhardt DT: Matrix metalloproteinases and tissue inhibitor of metalloproteinases: A review of their role in tumorigenesis and tissue invasion. Invasion Metastasis. 9:391–405. 1989.PubMed/NCBI
30	Seiki M: Membrane-type1 matrix metalloproteinase: A key enzyme for tumor invasion. Cancer Lett. 194:1–11. 2003. View Article : Google Scholar : PubMed/NCBI
31	Polette M, Nawrocki-Raby B, Gilles C, Clavel C and Birembaut P: Tumour invasion and matrix metalloproteinases. Crit Rev Oncol Hematol. 49:179–186. 2004. View Article : Google Scholar : PubMed/NCBI
32	Lin HJ, Su CC, Lu HF, Yang JS, Hsu SC, Ip SW, Wu JJ, Li YC, Ho CC, Wu CC and Chung JG: Curcumin blocks migration and invasion of mouse-rat hybrid retina ganglion cells (N18) through the inhibition of MMP-2, −9, FAK, Rho A and Rock-1 gene expression. Oncol Rep. 23:665–670. 2010.PubMed/NCBI
33	Tian T, Nan KJ, Guo H, Wang WJ, Ruan ZP, Wang SH, Liang X and Lu CX: PTEN inhibits the migration and invasion of HepG2 cells by coordinately decreasing MMP expression via the PI3K/Akt pathway. Oncol Rep. 23:1593–1600. 2010.PubMed/NCBI
34	Yang N, Hui L, Wang Y, Yang H and Jiang X: SOX2 promotes the migration and invasion of laryngeal cancer cells by induction of MMP-2 via the PI3K/Akt/mTOR pathway. Oncol Rep. 31:2651–2659. 2014. View Article : Google Scholar : PubMed/NCBI
35	Westermarck J and Kähäri VM: Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J. 13:781–792. 1999. View Article : Google Scholar : PubMed/NCBI
36	Wu YJ, Neoh CA, Tsao CY, Su JH and Li HH: Sinulariolide suppresses human hepatocellular carcinoma cell migration and invasion by inhibiting matrix metalloproteinase-2/-9 through MAPKs and PI3K/Akt signaling pathways. Int J Mol Sci. 16:16469–16482. 2015. View Article : Google Scholar : PubMed/NCBI